Lorenzo Barba, Christoph Vollmuth, Steffen Halbgebauer, Kathrin Ungethüm, Christian Hametner, Fabian Essig, Alexander M. Kollikowski, Mirko Pham, Michael K. Schuhmann, Peter U. Heuschmann, Patrick Oeckl, Petra Steinacker, Michele Romoli, Lucio D'Anna, Samir Abu-Rumeileh, Karl Georg Haeusler, Guido Stoll, Hermann Neugebauer, Markus Otto
{"title":"急性前循环缺血性卒中患者突触、神经元和神经胶质损伤的预后血清生物标志物。","authors":"Lorenzo Barba, Christoph Vollmuth, Steffen Halbgebauer, Kathrin Ungethüm, Christian Hametner, Fabian Essig, Alexander M. Kollikowski, Mirko Pham, Michael K. Schuhmann, Peter U. Heuschmann, Patrick Oeckl, Petra Steinacker, Michele Romoli, Lucio D'Anna, Samir Abu-Rumeileh, Karl Georg Haeusler, Guido Stoll, Hermann Neugebauer, Markus Otto","doi":"10.1111/ene.16581","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>We aimed to investigate the prognostic role of β-synuclein in comparison to that of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) for predicting functional outcome after acute ischemic stroke (AIS).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We measured serum concentrations of β-synuclein, NfL and GFAP 24 h after hospital admission in 213 consecutive patients with moderate-to-severe AIS. We investigated the association between serum biomarkers and radiological/clinical characteristics, 3-months mortality and functional outcome on the modified Rankin Scale (mRS).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In 213 patients with AIS [mean age: 76.1 (±12.5) years, 53.1% males, median NIHSS score on admission: 13 (IQR: 9–17)], higher levels of β-synuclein, NfL and GFAP were associated with higher NIHSS scores and with lower Alberta Stroke Program CT Score (ASPECTS) points on admission. Serum β-synuclein levels was significantly correlated with NfL (rho = 0.715, <i>p</i> < 0.001) and GFAP concentrations (rho = 0.684, <i>p</i> < 0.001). The inclusion of serum β-synuclein significantly improved the accuracy of prediction models without biomarkers for overall mortality (AUC: 0.836 vs. 0.752, <i>p</i> < 0.001) and mRS 3–6 vs. 0–2 (AUC: 0.812 vs. 0.624, <i>p</i> < 0.001). Combination models with NfL and/or GFAP showed a similar accuracy.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Serum β-synuclein may be used to assess synaptic damage/dysfunction and to predict 3-months clinical outcomes in patients with AIS.</p>\n </section>\n </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"32 1","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664725/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prognostic serum biomarkers of synaptic, neuronal and glial injury in patients with acute ischemic stroke of the anterior circulation\",\"authors\":\"Lorenzo Barba, Christoph Vollmuth, Steffen Halbgebauer, Kathrin Ungethüm, Christian Hametner, Fabian Essig, Alexander M. Kollikowski, Mirko Pham, Michael K. Schuhmann, Peter U. Heuschmann, Patrick Oeckl, Petra Steinacker, Michele Romoli, Lucio D'Anna, Samir Abu-Rumeileh, Karl Georg Haeusler, Guido Stoll, Hermann Neugebauer, Markus Otto\",\"doi\":\"10.1111/ene.16581\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>We aimed to investigate the prognostic role of β-synuclein in comparison to that of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) for predicting functional outcome after acute ischemic stroke (AIS).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We measured serum concentrations of β-synuclein, NfL and GFAP 24 h after hospital admission in 213 consecutive patients with moderate-to-severe AIS. We investigated the association between serum biomarkers and radiological/clinical characteristics, 3-months mortality and functional outcome on the modified Rankin Scale (mRS).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>In 213 patients with AIS [mean age: 76.1 (±12.5) years, 53.1% males, median NIHSS score on admission: 13 (IQR: 9–17)], higher levels of β-synuclein, NfL and GFAP were associated with higher NIHSS scores and with lower Alberta Stroke Program CT Score (ASPECTS) points on admission. Serum β-synuclein levels was significantly correlated with NfL (rho = 0.715, <i>p</i> < 0.001) and GFAP concentrations (rho = 0.684, <i>p</i> < 0.001). The inclusion of serum β-synuclein significantly improved the accuracy of prediction models without biomarkers for overall mortality (AUC: 0.836 vs. 0.752, <i>p</i> < 0.001) and mRS 3–6 vs. 0–2 (AUC: 0.812 vs. 0.624, <i>p</i> < 0.001). Combination models with NfL and/or GFAP showed a similar accuracy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Serum β-synuclein may be used to assess synaptic damage/dysfunction and to predict 3-months clinical outcomes in patients with AIS.</p>\\n </section>\\n </div>\",\"PeriodicalId\":11954,\"journal\":{\"name\":\"European Journal of Neurology\",\"volume\":\"32 1\",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-12-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664725/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ene.16581\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ene.16581","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：我们旨在研究β-突触核蛋白与神经丝轻链（NfL）和胶质纤维酸性蛋白（GFAP）在预测急性缺血性卒中（AIS）后功能结局中的预后作用。方法：连续213例中重度AIS患者入院后24 h，测定血清β-突触核蛋白、NfL和GFAP的浓度。我们研究了血清生物标志物与放射学/临床特征、3个月死亡率和改良Rankin量表（mRS）功能结局之间的关系。结果：213例AIS患者[平均年龄：76.1（±12.5）岁，53.1%男性，入院时NIHSS评分中位数：13 (IQR: 9-17)]，较高水平的β-synuclein、NfL和GFAP与入院时较高的NIHSS评分和较低的Alberta Stroke Program CT评分（ASPECTS）分相关。血清β-synuclein水平与脑膜炎（NfL）显著相关（rho = 0.715, p）。结论：血清β-synuclein可用于评估AIS患者突触损伤/功能障碍，并预测3个月临床预后。
Prognostic serum biomarkers of synaptic, neuronal and glial injury in patients with acute ischemic stroke of the anterior circulation
Background
We aimed to investigate the prognostic role of β-synuclein in comparison to that of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) for predicting functional outcome after acute ischemic stroke (AIS).
Methods
We measured serum concentrations of β-synuclein, NfL and GFAP 24 h after hospital admission in 213 consecutive patients with moderate-to-severe AIS. We investigated the association between serum biomarkers and radiological/clinical characteristics, 3-months mortality and functional outcome on the modified Rankin Scale (mRS).
Results
In 213 patients with AIS [mean age: 76.1 (±12.5) years, 53.1% males, median NIHSS score on admission: 13 (IQR: 9–17)], higher levels of β-synuclein, NfL and GFAP were associated with higher NIHSS scores and with lower Alberta Stroke Program CT Score (ASPECTS) points on admission. Serum β-synuclein levels was significantly correlated with NfL (rho = 0.715, p < 0.001) and GFAP concentrations (rho = 0.684, p < 0.001). The inclusion of serum β-synuclein significantly improved the accuracy of prediction models without biomarkers for overall mortality (AUC: 0.836 vs. 0.752, p < 0.001) and mRS 3–6 vs. 0–2 (AUC: 0.812 vs. 0.624, p < 0.001). Combination models with NfL and/or GFAP showed a similar accuracy.
Conclusions
Serum β-synuclein may be used to assess synaptic damage/dysfunction and to predict 3-months clinical outcomes in patients with AIS.
期刊介绍：
The European Journal of Neurology is the official journal of the European Academy of Neurology and covers all areas of clinical and basic research in neurology, including pre-clinical research of immediate translational value for new potential treatments. Emphasis is placed on major diseases of large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
